Adepitan A Owosho1, See Toh Yoong Liang2, Adi Z Sax3, Kant Wu3, SaeHee K Yom3, Joseph M Huryn3, Cherry L Estilo4. 1. College of Dental Medicine, University of New England, Portland, Maine, USA; Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2. National Dental Centre Singapore, Second Hospital Avenue, Singapore; Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3. Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 4. Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address: Estiloc@mskcc.org.
Abstract
OBJECTIVE: The aim of this study was to investigate the relationship between type of antiresorptive medication and medication-related osteonecrosis of the jaw (MRONJ) onset and the role of premedication dental evaluation (PMDE) in the prevention of MRONJ. STUDY DESIGN: Our database of patients with MRONJ was reviewed. The Kruskal-Wallis test was used to analyze the onset dose of the 3 frequent medication types associated with MRONJ. To evaluate the role of PMDE in the prevention of MRONJ, all patients on antiresorptive and/or antiangiogenic medications seen in the Dental Service of Memorial Sloan Kettering Cancer Center during a 10-year period were subclassified into 2 groups. Group I comprised patients seen for PMDE before the commencement of A/A and group II patients seen after prior exposure to antiresorptive and/or antiangiogenic medications. Fischer's exact test was used to compare the incidence of MRONJ in both groups. RESULTS: Patients on denosumab developed MRONJ earlier compared with zoledronate and pamidronate (P = .003). Group I had a significantly reduced incidence of MRONJ (0.9%) compared with group II (10.5%) (P < .0001). Dentoalveolar trauma as a precipitating factor between groups I and II was not statistically significant. CONCLUSIONS: Denosumab was associated with an earlier occurrence of MRONJ compared with zoledronate and pamidronate. The role of PMDE may be an effective preventive strategy in reducing the incidence of MRONJ.
OBJECTIVE: The aim of this study was to investigate the relationship between type of antiresorptive medication and medication-related osteonecrosis of the jaw (MRONJ) onset and the role of premedication dental evaluation (PMDE) in the prevention of MRONJ. STUDY DESIGN: Our database of patients with MRONJ was reviewed. The Kruskal-Wallis test was used to analyze the onset dose of the 3 frequent medication types associated with MRONJ. To evaluate the role of PMDE in the prevention of MRONJ, all patients on antiresorptive and/or antiangiogenic medications seen in the Dental Service of Memorial Sloan Kettering Cancer Center during a 10-year period were subclassified into 2 groups. Group I comprised patients seen for PMDE before the commencement of A/A and group II patients seen after prior exposure to antiresorptive and/or antiangiogenic medications. Fischer's exact test was used to compare the incidence of MRONJ in both groups. RESULTS:Patients on denosumab developed MRONJ earlier compared with zoledronate and pamidronate (P = .003). Group I had a significantly reduced incidence of MRONJ (0.9%) compared with group II (10.5%) (P < .0001). Dentoalveolar trauma as a precipitating factor between groups I and II was not statistically significant. CONCLUSIONS:Denosumab was associated with an earlier occurrence of MRONJ compared with zoledronate and pamidronate. The role of PMDE may be an effective preventive strategy in reducing the incidence of MRONJ.
Authors: Rogério Jardim Caldas; Héliton Spíndola Antunes; Camila de Oliveira Rodini Pegoraro; Fábio Ribeiro Guedes; Paulo Sérgio da Silva Santos Journal: Support Care Cancer Date: 2021-06-18 Impact factor: 3.603
Authors: Rodolfo Mauceri; Rita Coniglio; Antonia Abbinante; Paola Carcieri; Domenico Tomassi; Vera Panzarella; Olga Di Fede; Francesco Bertoldo; Vittorio Fusco; Alberto Bedogni; Giuseppina Campisi Journal: Support Care Cancer Date: 2022-03-16 Impact factor: 3.359
Authors: Lawrence Drudge-Coates; Tim Van den Wyngaert; Morten Schiødt; H A M van Muilekom; Gaston Demonty; Sven Otto Journal: Support Care Cancer Date: 2020-04-19 Impact factor: 3.603